Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report details a specific share repurchase transaction executed on May 26, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 600,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,323.50 pence; lowest price paid was 1,313.50 pence.
- Treasury Holdings (Settled): 495,699,284 shares (8.76% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,324,284 shares (9.64% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,161,003,460 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 600,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 9.64% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,161,003,460) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (9.64% including unsettled shares).
- Note that the repurchased shares are intended to be held in Treasury.